PP 0121

Drug Profile

PP 0121

Alternative Names: PHAGOBURN E coli phage - Pherecydes; PP0121

Latest Information Update: 19 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pherecydes Pharma
  • Class Coliphages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Burn infections; Escherichia coli infections

Most Recent Events

  • 01 Jul 2015 Phase-I/II clinical trials in Burn infections in France (Topical) (NCT02116010)
  • 01 Jul 2015 Phase-I/II clinical trials in Escherichia coli infections in France (Topical) (NCT02116010)
  • 03 Jun 2014 Pherecydes Pharma plans a phase I/II trial for Burn infections caused by Escherichia coli in Belgium, France and Switzerland (Topical) (NCT02116010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top